Evidence map›Paper›PMID 40005778›Full record

ArticleMicroorganisms2025

Phenotypic Ultra-Rapid Antimicrobial Susceptibility Testing for Ceftazidime-Avibactam: In Support of Antimicrobial Stewardship.

Inês Martins-Oliveira, Blanca Pérez-Viso, Rosário Gomes, David Abreu, Ana Silva-Dias, Rafael Cantón, Cidália Pina-Vaz

Abstract read
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Inês Martins-OliveiraFASTinov, S.A., 4200-135 Porto, Portugal.
Blanca Pérez-VisoServicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-0693-597X
Rosário GomesFASTinov, S.A., 4200-135 Porto, Portugal.
David AbreuFASTinov, S.A., 4200-135 Porto, Portugal.
Ana Silva-DiasFASTinov, S.A., 4200-135 Porto, Portugal.
Rafael CantónServicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-1675-3173
Cidália Pina-VazFASTinov, S.A., 4200-135 Porto, Portugal.

Funding

CIBERINFEC(CB21/13/00084), Instituto de Salud Carlos III, Spain CB21/13/00084CINTESIS, R&D Unit reference UIDB/4255/2020)European Project IN-ARMOR 101080889: Horizon-HLTH-2022-disease-06-two-stage, reference 101080889
6 · The paper itself

Abstract

Ceftazidime-avibactam (CZA) is a potent broad-spectrum drug combination covering extended-spectrum β-lactamases, AmpC, and carbapenemases of class A and D, OXA-48-type producers. Rapid antimicrobial susceptibility testing is crucial for the timely de-escalation/escalation of therapy. We evaluate CZA susceptibility using the CE-IVD FASTgramneg kit (FASTinov

Indexed as

antibiotic escalation/de-escalationantimicrobial susceptibility testingceftazidime–avibactamflow cytometryGram-negative bacteriarapid diagnostics

Identifiers

PMID40005778
PMCPMC11858068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.